JPJinhui Peng

Jinhui Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinhui Peng has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Arthroscopic Management for Hip Joint Septic Arthritis: A Retrospective Study of 28 Adult Patients With a Minimum 3‐Year Follow‐Up

    by Shu Chen, Yaguang Han, Yiqin Zhou, Jiahua Shao, Zheru Ding, Jia Cao, Haobo Li, Lei Zhang, Qirong Qian, Jinhui Peng

    Objective: Hip septic arthritis is a relatively rare yet severe cause of acute hip pain, with the potential to rapidly destroy articular cartilage, lead to osteonecrosis, and cause osteomyelitis. This life‐threatening infection demands early diagnosis and appropriate treatment. Our study aims to assess the surgical safety and efficacy of arthroscopic management for this condition and to optimize the arthroscopic treatment protocol by customizing surgical interventions based on intraoperative findings and disease stages. Methods: We conducted a retrospective study of 28 patients (18 females, 10 males; average age of 49 ± 10.5 years) from January 2018 to March 2022. Diagnosis of hip septic arthritis was confirmed via synovial fluid examination, culture, or synovial pathology. Patients underwent arthroscopic joint lavage, synovectomy, and drainage tailored to the intraoperative situation and the Gächter stage. Antibiotics were administered based on drug‐sensitivity results or empirically. We recorded and analyzed symptoms, comorbidities, stages, inflammatory marker levels, culture results, antibiotic duration, outcomes, and complications. Results: The mean time from symptom onset to surgery was 10.2 ± 8.6 (range, 4–45) days. All patients had elevated inflammatory markers. Pre‐operative bacterial cultures were positive in 6 cases, and post‐operative cultures were positive in 21 cases. Staphylococcus aureus was the most frequently detected pathogen (10 cases), accounting for approximately 47.6% of the positive culture cases. Antibiotic therapy lasted 4–6 weeks. The C‐reactive protein normalized on average 43 days after surgery; the erythrocyte sedimentation rate normalized 54 days postoperatively. At final follow‐up (mean 42 months), the visual analog scale score decreased from 6.6 ± 1.3 to 1.3 ± 0.2 ( p = 0.003), and the modified Harris Hip Score improved from 52 ± 8.1 to 85 ± 8.6 ( p = 0.001). Infection was controlled in all patients within 6 months. Two patients (Gächter stage III/IV) had recurrent infections at 8 and 11 months, successfully treated with repeat arthroscopy. Gächter stage III or IV was a significant risk factor for recurrence. Two patients underwent total hip arthroplasty due to secondary osteoarthritis and osteonecrosis. No major complications occurred. Conclusion: Stage‐based arthroscopic lavage, synovectomy, and drainage combined with antibiotics is effective for hip septic arthritis. The optimized procedure offers a safe and effective option, particularly for early‐stage (Gächter I–II) disease, while advanced stages (III–IV) require cautious management due to higher recurrence risk.

  • Oct4 facilitates chondrogenic differentiation of mesenchymal stem cells by mediating CIP2A expression

    by Lexiang Li, Qiwei Fu, Jiahua Shao, Bo Wang, Zheru Ding, Shuai Yuan, Jinhui Peng, Wei Xin, Jun Zhu, Yi Chen

    Bone development and cartilage formation require strict modulation of gene expression for mesenchymal stem cells (MSCs) to progress through their differentiation stages. Octamer-binding transcription factor 4 (Oct4) expression is generally restricted to developing embryonic pluripotent cells, but its role in chondrogenic differentiation (CD) of MSCs remains unclear. We therefore investigated the role of Oct4 in CD using a microarray, quantitative real-time polymerase chain reaction, and western blotting. The expression of Oct4 was elevated when the CD of cultured MSCs was induced. Silencing Oct4 damaged MSC growth and proliferation and decreased CD, indicated by decreased cartilage matrix formation and the expression of Col2a1, Col10a1, Acan, and Sox9. We found a positive correlation between the expression of CIP2A, a natural inhibitor of protein phosphatase 2A (PP2A) and that of Oct4. Cellular inhibitor of PP2A (CIP2A) expression gradually increased after CD. Overexpression of CIP2A in MSCs with Oct4 depletion promoted cartilage matrix deposition as well as Col2a1, Col10a1, Acan, and Sox9 expression. The chondrogenic induction triggered c-Myc, Akt, ERK, and MEK phosphorylation and upregulated c-Myc and mTOR expression, which was downregulated upon Oct4 knockdown and restored by CIP2A overexpression. These findings indicated that Oct4 functions as an essential chondrogenesis regulator, partly via the CIP2A/PP2A pathway.


  • Chemoselective ligation assisted DNA walker for analysis of double targets

    by Tianxiang Xue, Longfei Tang, Xiquan Yue, Lili Niu, Jinhui Peng, Juan Zhang

  • Open Access

    Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women

    by Yi Chen, Jun Zhu, Yiqin Zhou, Jinhui Peng, Bo Wang

    Denosumab, a human monoclonal antibody, acts against the receptor activator of nuclear factor-κB ligand and is a promising antiresorptive agent in patients with osteoporosis. This study aimed to update the efficacy and safety of denosumab vs. placebo in osteoporosis or low bone mineral density (BMD) postmenopausal women. PubMed, Embase, Cochrane library, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) reporting the efficacy and safety data of denosumab vs. placebo in osteoporosis or low BMD postmenopausal women. A random-effects model was used to calculate pooled weight mean differences (WMDs) or relative risks (RRs) with corresponding 95% confidence intervals (CIs) for treatment effectiveness of denosumab vs. placebo. Eleven RCTs including 12,013 postmenopausal women with osteoporosis or low BMD were preferred for the final meta-analysis. The summary results indicated that the percentage change of BMD in the denosumab group was greater than that of BMD in placebo at 1/3 radius (WMD: 3.43; 95%CI: 3.24–3.62; p < 0.001), femoral neck (WMD: 3.05; 95%CI: 1.78–4.33; p < 0.001), lumbar spine (WMD: 6.25; 95%CI: 4.59–7.92; p < 0.001), total hip (WMD: 4.36; 95%CI: 4.07–4.66; p < 0.001), trochanter (WMD: 6.00; 95%CI: 5.95–6.05; p < 0.001), and total body (WMD: 3.20; 95%CI: 2.03–4.38; p < 0.001). Moreover, denosumab therapy significantly reduced the risk of clinical fractures (RR: 0.57; 95%CI: 0.51–0.63; p < 0.001), nonvertebral fracture (RR: 0.83; 95%CI: 0.70–0.97; p = 0.018), vertebral fracture (RR: 0.32; 95%CI: 0.25–0.40; p < 0.001), and hip fracture (RR: 0.61; 95%CI: 0.37–0.98; p = 0.042). Finally, denosumab did not cause excess risks of adverse events. These findings suggested that postmenopausal women receiving denosumab had increased BMDs and reduced fractures at various sites without inducing any adverse events.


  • Prx II reduces oxidative stress and cell senescence in chondrocytes by activating the p16-CDK4/6-pRb-E2F signaling pathway

    by J-H Shao, Q-W Fu, L-X Li, R. Zhou, N. Liu, J-H Peng, Y. Chen

    OBJECTIVE: Osteoarthritis (OA) is a common clinical degenerative disease and has a high incidence in the elderly. The purpose of this study was to explore the anti-oxidative stress and anti-aging effects of Peroxiredoxin (Prx II) on articular chondrocytes, as well as its molecular mechanism. MATERIALS AND METHODS: Articular cartilage tissues and culture human articular chondrocytes were selected. By constructing Prx II overexpressing lentivirus, the effects of Prx II on oxidative stress and cell senescence in chondrocytes were studied. Besides, the p16 overexpression lentivirus was constructed to investigate the effect of Prx II on the p16-CD-K4/6-pRb-E2F signaling pathway (p16 signaling pathway). RESULTS: Articular cartilage tissues in patients with OA and IL-1 beta-induced chondrocytes expressed lower Prx II and had higher p16 signaling pathway activity. The overexpression of Prx II significantly increased the expression of SOD1 and SOD2 and decreased the expression of beta-gal and P53/P21, indicating that Prx II can reduce the oxidative stress and senescence level of chondrocytes. Moreover, the overexpression of Prx II increased the expression of p16 signaling pathway-related molecules and the activation of the p16 signaling pathway attenuated the anti-oxidative stress and anti-aging effects of Prx II. CONCLUSIONS: Prx II can inhibit the p16 signaling pathway in chondrocytes to reduce the level of aging in chondrocytes, thereby reducing the level of oxidative stress in chondrocytes, and ultimately inhibiting the progression of OA.